Integra Lifesciences (IART) AI Stock Analysis

• Market Cap: $944.98M
• Dividend Yield: N/A
• Average Volume (3M): 1.50M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.50
• Revenue Growth: 6.19%
• EPS Growth: -174.69%
• Country: US
• Employees: 4,396
• Sector: Healthcare
• Sector Strength: 58
• Industry: Medical - Devices
• EPS (TTM): 0.41
• Shares Outstanding: 77,712,270
• 10 Day Avg. Volume: 1,348,294
• 30 Day Avg. Volume: 1,495,639
• PEG Ratio: 2.86
• Price to Book (P/B): 2.58
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 21.41
• Enterprise Value/Market Cap: 6.15
• Enterprise Value/Revenue: 0.91
• Enterprise Value/Gross Profit: 5.46
• Enterprise Value/Ebitda: 6.43
• 1Y Price Target: $17.17
• Price Target Upside: 41.20% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 8

• Rating: 52 Neutral
• Price Target: $13.00 ▲(6.91%Upside)

Integra Lifesciences is currently facing considerable challenges. The most significant factors impacting the score are financial performance issues, driven by profitability concerns and cash flow challenges. Technical analysis indicates a bearish trend, and valuation metrics reflect difficulties. While the earnings call highlighted some achievements, ongoing operational issues and external impacts such as tariffs contribute to a cautious outlook.

Positive Factors

Future Growth Potential

Despite challenges, there is potential for a multi-year turnaround under new leadership if regulatory issues are managed effectively.

Proactive Management

Management has implemented a Compliance Master Plan and partnered with third-party consulting firms to address quality issues, showing proactive steps towards improvement.

Negative Factors

Financial Guidance

EPS guidance is now $2.19-2.29 versus $2.41-2.51 prior to today's release.

Operational Challenges

The company is facing ongoing issues with shipholds and capacity, which are affecting its overall performance.

Revenue Projections

The FY25 revenue guide was $30m or 2% below Street consensus as supply challenges are expected to weigh on Q1 growth.

Integra Lifesciences Business Overview & Revenue Model

Company Description

Integra Lifesciences (IART) is a global medical technology company specializing in the development, manufacture, and marketing of innovative surgical implants and medical devices. The company primarily operates in the neurosurgery, orthopedic, and reconstructive surgery sectors, offering a wide range of products such as regenerative tissue technologies, neurosurgical and critical care solutions, and orthopedic extremity implants. Its products are designed to address the needs of healthcare professionals and improve patient outcomes across various clinical environments.

How the Company Makes Money

Integra Lifesciences generates revenue through the sale of its medical devices and surgical implants to hospitals, surgical centers, and healthcare providers worldwide. The company's revenue streams are primarily derived from its two main business segments: Codman Specialty Surgical and Tissue Technologies. Codman Specialty Surgical focuses on products used in neurosurgery and critical care, while Tissue Technologies offers regenerative technologies and surgical reconstruction solutions. Integra Lifesciences also benefits from strategic partnerships and collaborations with healthcare institutions and research organizations, which help expand its product offerings and market reach. Additionally, the company invests in research and development to innovate and enhance its product portfolio, thereby maintaining a competitive edge and driving sales growth.

Integra Lifesciences Financial Statement Overview

Summary

Integra Lifesciences faces mixed financial performance with stable revenue growth but significant profitability concerns due to recent losses. The balance sheet is moderately strong with balanced leverage, but cash flow challenges persist with a significant decline in free cash flow. The company's financial flexibility is impacted, necessitating a focus on operational efficiency and cash generation.

Income Statement

Integra Lifesciences has demonstrated stable revenue growth with a TTM increase of 0.86% compared to the previous year. However, profitability measures such as net profit margin are concerning due to recent losses, leading to a negative net income. The gross profit margin remains strong at 65.54%, showing efficient cost management, but the EBIT and EBITDA margins are relatively low at 2.91% and 9.30%, respectively, indicating challenges in operational efficiency.

Balance Sheet

The company's balance sheet reveals a moderate debt-to-equity ratio of 1.32, reflecting a balanced approach to leveraging. The equity ratio stands at 37.61%, indicating a stable capital structure. However, the return on equity has been affected by the net losses, suggesting room for improvement in generating shareholder value.

Cash Flow

The cash flow situation shows a significant decline in free cash flow, down 86.13% year-over-year, raising concerns about the company's ability to generate cash. The operating cash flow to net income ratio is negative due to losses, but cash from operations remains positive, indicating some resilience in cash generation despite profitability issues.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.62B	1.61B	1.54B	1.56B	1.54B	1.37B
	Gross Profit
1.06B	882.06M	888.39M	970.31M	944.64M	851.03M
	EBIT
47.23M	28.41M	111.53M	238.92M	197.23M	151.37M
	EBITDA
150.97M	193.29M	274.01M	391.10M	366.33M	267.93M
	Net Income Common Stockholders
-28.95M	-6.94M	67.74M	180.55M	169.07M	133.89M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
273.30M	273.57M	309.10M	456.66M	513.45M	470.17M
	Total Assets
4.05B	4.04B	3.78B	3.89B	3.78B	3.62B
	Total Debt
2.02B	1.98B	1.68B	1.62B	1.65B	1.66B
	Net Debt
1.78B	1.74B	1.41B	1.16B	1.14B	1.19B
	Total Liabilities
2.53B	2.49B	2.19B	2.09B	2.10B	2.10B
	Stockholders Equity
1.52B	1.55B	1.59B	1.80B	1.68B	1.51B
Cash Flow		Free Cash Flow
3.46M	24.96M	73.09M	217.38M	264.35M	139.94M
	Operating Cash Flow
102.37M	129.38M	139.96M	264.47M	312.43M	203.83M
	Investing Cash Flow
-372.76M	-390.81M	-94.18M	-58.58M	-161.44M	-68.07M
	Financing Cash Flow
-85.44M	237.86M	-229.93M	-251.95M	-98.23M	121.63M

Integra Lifesciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 12.16
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IART, the sentiment is Negative. The current price of 12.16 is below the 20-day moving average (MA) of 13.00, below the 50-day MA of 14.73, and below the 200-day MA of 20.14, indicating a bearish trend. The MACD of -0.52 indicates Negative momentum. The RSI at 36.83 is Neutral, neither overbought nor oversold. The STOCH value of 26.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IART.

Integra Lifesciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UFPT	81 Outperform	$1.80B	28.54	19.36%	―	34.43%	31.90%
CNMD	72 Outperform	$1.66B	14.03	12.96%	1.49%	4.20%	43.62%
AORT	68 Neutral	$1.21B	―	-7.25%	―	5.94%	-115.82%
LIVN	66 Neutral	$2.50B	30.62	-19.69%	―	7.97%	-592.40%
AHCO	63 Neutral	$1.16B	15.16	5.12%	―	-0.05%	―
Sector *	54 Neutral	$5.37B	3.26	-45.10%	3.30%	16.81%	0.02%
IART	52 Neutral	$944.98M	―	-1.85%	―	6.19%	-174.69%

Integra Lifesciences Corporate Events

Integra Lifesciences Amends Credit Agreement for Stability

On June 6, 2025, Integra LifeSciences amended its Credit Agreement to adjust its financial covenants, particularly increasing the maximum consolidated total leverage ratio through various fiscal quarters until March 2027. This amendment, effective during the Covenant Relief Period, also imposes temporary restrictions on investments, indebtedness, and intellectual property transactions, aiming to stabilize the company’s financial operations without increasing its total debt.

The most recent analyst rating on (IART) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on Integra Lifesciences stock, see the IART Stock Forecast page.

Integra Lifesciences Approves Equity Plan Amendment

At its 2025 Annual Meeting of Stockholders on May 9, Integra LifeSciences announced the approval of an amendment to its equity incentive plan, increasing the number of shares available for awards by 2,200,000. Additionally, the stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year and approved executive compensation on an advisory basis. The Board also announced the transition of Dr. Stuart M. Essig from Executive Chairman to non-executive Chairman, effective July 1, 2025, with no disagreements cited regarding company operations.

The most recent analyst rating on (IART) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on Integra Lifesciences stock, see the IART Stock Forecast page.